Phase II trial of interferon‐α‐2a plus psolaren with ultraviolet light A in patients with cutaneous T‐cell lymphoma
Open Access
- 23 July 2002
- Vol. 95 (3), 569-575
- https://doi.org/10.1002/cncr.10706
Abstract
PURPOSE To evaluate the efficacy and side effects of psolaren with ultraviolet light A (PUVA) and interferon‐alpha‐2a (IFN‐α‐2a) in patients with mycosis fungoides (MF) and Sézary syndrome (SS). PATIENTS AND METHODS From May 1993 to January 1999, 63 symptomatic patients with all stages of MF and SS were treated in a prospective Phase II trial with systemic escalating doses of IFN‐α‐2a combined with PUVA for 1 year, followed by indefinite PUVA maintenance in complete responding patients. RESULTS Sixty‐three patients were enrolled (Stage IA, n = 6; IB, n = 37; IIA, n = 3; IIB, n = 3; III, n = 12; IVA, n = 2). Ten patients had received previous therapy. The median follow‐up duration for the entire cohort is 37 months. Of 63 patients, 51 achieved a complete response (CR; 74.6%) or partial response (PR; 6%) to therapy. The median response duration is 32 months. The 5‐year overall survival rate is 91% and the 5‐year disease‐free survival rate is 75%. No life‐threatening side effects were observed. Five patients stopped IFN‐α‐2a therapy due to toxicity. Eighty‐four percent of the patients received more than 75% of the planned dose (12 million units three times a week). CONCLUSIONS This combination of IFN‐α‐2a and phototherapy is an effective and safe therapy for patients with symptomatic MF. Cancer 2002;95:569–75. © 2002 American Cancer Society. DOI 10.1002/cncr.10706Keywords
This publication has 27 references indexed in Scilit:
- Prognostic factors and evaluation of mycosis fungoides and Sézary syndromeJournal of the American Academy of Dermatology, 1997
- Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: A 10-year experience at a single institutionJournal of the American Academy of Dermatology, 1996
- Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoidsJournal of the American Academy of Dermatology, 1991
- Photopheresis for the treatment of cutaneous T cell lymphomaJournal of the American Academy of Dermatology, 1990
- Activity of Fludarabine Monophosphate in Patients With Advanced Mycosis Fungoides: A Southwest Oncology Group StudyJNCI Journal of the National Cancer Institute, 1990
- Interferon Alfa-2a Combined With Phototherapy in the Treatment of Cutaneous T-Cell LymphomaJNCI Journal of the National Cancer Institute, 1990
- A Randomized Trial Comparing Combination Electron-Beam Radiation and Chemotherapy with Topical Therapy in the Initial Treatment of Mycosis FungoidesNew England Journal of Medicine, 1989
- Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphomaJournal of the American Academy of Dermatology, 1989
- Psoralen photochemotherapyJournal of the American Academy of Dermatology, 1987
- Treatment of Cutaneous T-Cell Lymphoma by Extracorporeal PhotochemotherapyNew England Journal of Medicine, 1987